Text Size: a  |   a 

An MS Study on MD 1003 That You May Want To Be a Part Of

August 16, 2017

MD1003 is a high dose of biotin, a form of Vitamin B. When the results of an earlier MD1003 study were announced back in the spring of 2016, the principal author called them “especially remarkable.” That study showed that MD1003 slowed MS progression and improved the walking of more than 12 percent of the study subjects. “This is the first time that a drug has reversed the progression of the disease in a statistically significant proportion of patients,” Ayman Tourbah, professor at CHU de Reims, France, said in a press release. (This, however, may not be entirely correct as this kind of reversal has been reported by some users of the DMD Lemtrada).

Now, as reported a few months ago in a Multiple Sclerosis News Today story, a larger MD1003 study is underway. The researchers’ goal is to recruit 600 MS patients. They’re particularly interested in signing up patients whose gait is impaired. Half of the patients will take a capsule of MD1003 three times a day. The other half will receive a placebo. Investigators hope to show that using high-dose biotin (300 mg) will improve patient’s Expanded Disability Standard Scale (EDSS) score, or improve patients’ walking speeds by 20 percent on the 25-foot walking test.

To be eligible to participate an MS patient must be:

  • 18-65 years old
  • Diagnosed with primary or secondary progressive MS
  • Have had disability progression within 2 years prior to entering the study
  • An EDSS rating between 3.5 and 6.5
  • A 25-foot walking speed of less than 40 seconds

There are other, more detailed requirements. To see if you would qualify for this study, you can click here.